Yun Tian

Yun Tian


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
STSara Tartof
Sara Tartof
LCLie Hong Chen
Lie Hong Chen
YTYun Tian
Yun Tian
RWRong Wei
Rong Wei
TITheresa Im
Theresa Im
LQLei Qian
Lei Qian
Antibiotic stewardship programs (ASPs) have demonstrated success at reducing costs, yet there is limited quality evidence of their effectiveness to reduce infections of high-profile drug-resistant organisms. This retrospective cohort study included all Kaiser Permanente Southern California (KPSC) members hospitalized in 9 KPSC hospitals aged ≥18 years from January 1, 2008 to December 31, 2016. We measured the impact of staggered ASP implementation on consumption of 18 ASP-targeted antibiotics using generalized linear mixed effects models. We used multivariable generalized linear mixed effects models to estimate the adjusted effect of ASP on rates of infection with drug-resistant organisms. Analyses were adjusted for confounding by time, cluster effects, and patient-level and hospital-level characteristics. We included 765,111 hospitalizations (288,257 pre-ASP, 476,854 post-ASP). By defined daily dose, we found a 6.1% (-7.5% - -4.7%) overall decrease in use of antibiotics post-ASP, and by days of therapy, we detected a 4.3% (-5.4% - -3.1%) decrease in overall use of antibiotics. The number of prescriptions increased post-ASP (1.04 [1.03–1.05]). In adjusted analyses, we detected an overall increase of VRE infection following ASP (1.37 [1.10-1.69]). We did not detect a change in the rates of ESBL, CRE and MDR Pseudomonas aeruginosa following ASP. ASPs with successful reductions in consumption of targeted antibiotics may not see changes in infection rates with antibiotic-resistant organisms in the 2 to 6 years post-implementation. There are likely differing timescales for reversion to susceptibility across organisms and antibiotics, and unintended consequences from compensatory prescribing may occur.

29 December 2022 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
MCMiaojuan Chen
Miaojuan Chen
YPYue Pan
Yue Pan
HLHanbo Liu
Hanbo Liu
FNFen Ning
Fen Ning
QLQinsheng Lu
Qinsheng Lu
GLGendie Lash
Gendie Lash

18 February 2022 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
LLLin Liu
Lin Liu
JZJinglan Zhu
Jinglan Zhu
YTYun Tian
Yun Tian
Background: Case reports of bladder carcinosarcoma (BCS) indicate high rates of recurrence and metastasis and poor prognosis. However, the differences in clinicopathologic characteristics and prognosis between BCS and conventional bladder cancer histologies (transitional cell carcinoma [TCC], squamous cell carcinoma [SCC] and adenocarcinoma [AC]) have not been fully clarified in a large study. Therefore, we conducted a large population‐based study to further investigate these differences.Patients and methods: Information on patients with BCS and conventional bladder cancer (TCC, SCC or AC) was extracted from the Surveillance, Epidemiology, and End Results database. Categorical variables were compared using Pearson's chi‐squared test or Fisher's exact test. Survival analysis was carried out using the Kaplan–Meier method, and differences in survival were assessed using the log‐rank test. Propensity score matching analysis was conducted to calibrate the differences between the baseline characteristics, after which Cox regression analysis was applied to calculate the hazard ratios and 95% confidence intervals of BCS compared to other subtypes. Subgroup analysis and related interaction were tested to evaluate the consistency and heterogeneity of results.Results: We enrolled 152 patients with BCS and 180,196 patients with TCC, SCC or AC. Our results showed that BCS was associated with poor differentiation, advanced stage and an unfavourable overall survival and cancer‐specific survival. BCS had a worse prognosis than TCC and AC, but no statistically significant difference in survival was noted between BCS and SCC.Conclusions: BCS is a more aggressive bladder cancer than TCC and AC but is comparable to SCC. These findings broaden our understanding of BCS and may be helpful in clinical practice.

8 March 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
LZLisi Zeng
Lisi Zeng
XHXubo Huang
Xubo Huang
YTYun Tian
Yun Tian
JHJinxia Huang
Jinxia Huang
HLHuiyan Liu
Huiyan Liu
SCShuzhong Cui
Shuzhong Cui
Background: Gastric cancer (GC) is one of the most common cancer types, especially in Asian countries. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve the progression-free survival among gastric cancer patients with peritoneal metastases; however, not all patients demonstrate response to HIPEC.Methods: Biomarkers are needed to select patients for effective treatment of HIPEC. Here, we performed whole-exome sequencing on tumor samples from 18 gastric cancer patients who received HIPEC treatment and assessed the association between genomic mutation features and progression-free survival. Exome sequencing was further conducted on tumor samples from additional 15 gastric cancer patients as a replication study.Results: The tumor mutational burden (TMB) was significantly higher in the group of patients with a better response to HIPEC treatment than that of the others. Kaplan–Meier survival curve showed that patients with high TMB had a significantly longer survival time than that in patients with low TMB. This discovery was validated in the replication cohort. Genes bearing mutations recurrently and selectively in patients with better response to HIPEC were found in the two cohorts.Conclusion: We found that higher TMB is significantly associated with better response to HIPEC. Our results provide useful hints for prognostic stratification of HIPEC treatment.

17 May 2022 in Research Square
Verified
Preprint
Open access
PDF file
LLLin Liu
Lin Liu
YZYaqing Zhu
Yaqing Zhu
CZCuiling Zhou
Cuiling Zhou
YTYun Tian
Yun Tian
Introduction Carcinosarcoma (CS) is a rare malignant tumor. Little is known about the epidemiological feature of the disease in literature. Our aim is to offer the largest and latest analysis of the incidence, mortality, and survival of CS. Methods Data of CS from the Surveillance, Epidemiology, and End Results (SEER) database (SEER-9 incidence database and SEER-9 incidence-based mortality database) were adopted. Incidence, mortality, and survival analyses were performed by SEER*Stat software. We used annual percentage change (APC) to evaluate the trends in incidence and mortality. Results Incidence rate increased from 0.36/100,000 to 0.83/100,000 with an APC of 3.4% from 1975 to 2018. Mortality rate followed a similar pattern of increase at an APC of 3.2% from 0.07/100,000 in 1975 to 0.54/100,000 in 2018. Most CS occurred in the female genital system and the 5-year survival rate of all patients was 34.9%. Conclusion CS is an aggressive tumor with increasing incidence and mortality trends. This tumor, especially CS in the female genital system, is no longer considered to be a rare tumor in the near future. This research will broad our knowledge for CS as well as provide insight for clinicians.